Clinical Trial Update: A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer) [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating the combination of abemaciclib with abiraterone in men with metastatic hormone-sensitive prostate cancer has results posted …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• VERZENIO (ABEMACICLIB)
• Zytiga (abiraterone acetate)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Prostatic Neoplasms, Neoplasm Metastasis | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-06-27